Objectives: Plasma levels of immunoreactive endothelin-1 (ET-1) are raised in chronic heart failure. Whether plasma ET-1 contributes to the haemodynamic derangement found in chronic heart failure is not known. We investigated the effects of exogenous ET-1 on the pulmonary and systemic vasculature in patients with left ventricular systolic dysfunction (LVD), with or without overt heart failure. Methods: ET-1 was infused at 1, 5 and 15 pmol / min into a distal pulmonary artery of ten patients with LVD to achieve plasma concentrations of ET-1 similar to those found in patients with heart failure and pulmonary hypertension. Haemodynamics were measured using a pulmonary thermodilution catheter and an arterial line. Intravascular Doppler and local pulmonary angiography were used to assess local pulmonary blood flow in the first four patients. Conclusions: Exogenous ET-1, when infused to achieve plasma concentrations similar to those in severe heart failure and pulmonary hypertension, causes systemic but not pulmonary vasoconstriction.
Introduction
both receptors have been shown to mediate vasoconstriction, the endothelial ET receptor may also mediate B
The endothelins are a family of potent vasoconstrictor vasodilatation via nitric oxide and / or prostaglandins [7] . peptides [1, 2] . Endothelin-1 (ET-1) is the predominant Plasma concentrations of ET-1 have been measured by isoform expressed in the human vasculature [3] . ET-1, extraction-based radioimmunoassays with variable crostogether with the C-terminal fragment, are formed by sreactivity to big ET-1 and the C-terminal fragment and cleavage of big ET-1, a biologically inactive propeptide, a have consistently been shown to be elevated in patients process catalysed by one or more ET converting enzymes with moderate or severe heart failure [8] [9] [10] [11] [12] [13] . Plasma [4] . ET-1 acts via at least two receptor subtypes, denoted concentrations of ET-1 are increased in proportion to the ET and ET [5, 6] . ET receptors have selective affinity symptomatic and haemodynamic severity of chronic heart A B A
for ET-1 and are expressed primarily on vascular smooth failure (CHF) [14] . Several authors have noted a positive muscle cells and cardiac myocytes. ET receptors, which relationship between plasma immunoreactive ET-1 (irET) B have equal affinity for each ET isoform, are expressed on and pulmonary haemodynamics measurements, in particuboth endothelial cells and vascular smooth muscle. Whilst lar pulmonary vascular resistance (PVR) and the ratio of pulmonary to systemic vascular resistance (the resistance ratio) [10, [15] [16] [17] [18] . It is not yet clear however, whether the relationship between plasma ET-1 and PVR is one of association or cause and effect. It is difficult to characterise pulmonary artery responses to ET-1 in vivo, as pulmonary haemodynamic indices closely reflect changes in systemic haemodynamics. One possible approach is to infuse ET-1 locally to achieve high local concentrations of ET-1 in the pulmonary vascular bed without increasing concentrations in the systemic vasculature. Therefore we infused ET-1 in a range of concentrations directly into the distal pulmonary artery of patients with left ventricular dysfunction with or without overt heart failure and used intravascular Doppler ultrasound and local pulmonary angiography to study local vascular effects. 
Methods
sulin dependent diabetes. Further characteristics are given in Table 1 .
Patient selection

Study protocols
Patients with chronic left ventricular systolic dysfunction (LVD) were eligible for study. LVD was defined as a Studies were conducted with the approval of the local left ventricular ejection fraction (LVEF) of ,40%. LVEF ethics committee and with the written, informed consent of was measured by echocardiography using Simpson's bipeach patient. Cardiac medications were withheld for a lane method (except in one case where radionuclide minimum of 24 h before the study. Patients were fasted for ventriculogram was used). Patients with severe coronary 4 h prior to the study. Studies took place in the cardiac disease, valvular heart disease, atrial fibrillation, insulin catheterisation laboratory. A 7F thermodilution catheter dependent diabetes, uncontrolled hypertension and chronic was positioned in a distal pulmonary artery percutaneously renal impairment (creatinine .200 mmol / ml) were exvia a femoral vein under fluoroscopic control. In the first cluded.
four patients a 6F multipurpose catheter was also passed to the same pulmonary artery to allow intravascular Doppler 2.2. Patient characteristics studies. A 4F femoral arterial line was also placed to allow continuous intraarterial blood pressure monitoring. Heparin Ten patients aged 51-74 (mean 62) years took part in (2500 units) was given as standard prophylaxis against the study. Their mean LVEF was 2766 (S.D.). One patient thrombus formation. had a history of hypertension and one patient had noninAn outline of the study protocol is shown in Fig. 1 . Baseline haemodynamic measurements were obtained at a Blood samples were obtained from all patients from a minimum of 15 min postinstrumentation. Heart rate (HR, peripheral vein after 30 min of supine rest 2 h prior to the beats per min) was recorded from a precordial electrostudy. In six patients samples were also taken from the cardiographic lead. Systemic arterial, right atrial, pulmonfemoral artery at baseline prior to SNP infusion, after ary arterial and pulmonary capillary wedge pressure reestablishment of a baseline prior to ET-1 infusion, at the (PCWP) measurements were made simultaneously end of each dose of ET-1, and at 5 and 15 min of recovery (mmHg). Cardiac output was measured (in triplicate) at (see Fig. 1 ). each time point (see Fig. 1 ) by thermodilution and cardiac 2 index derived (CI, l / min / m ). Systemic vascular resist-2.5.2. Control subjects and patients with LVD ance (SVR) and PVR were calculated from standard Blood samples were also taken from a peripheral vein formula [19] . Both resistance values were expressed as 5 from a further 17 patients with LVD undergoing haemodynes s / cm . dynamic evaluation (cardiac medications were withheld for After baseline values were established sodium nitro-24 h). Eight of these patients had a mean pulmonary artery prusside (SNP) was infused into the pulmonary artery pressure of .30 mmHg. A total of 21 control subjects under study at 0.56 and 1.12 mg / kg / min to assess vasodiwere also studied: 11 subjects with no history of cardiac lator reserve. Five patients also received 1.68 mg / kg / min. disease, a normal electrocardiogram, and taking no mediAfter 5 min of each dose a complete set of haemodynamic cations and a further ten patients with chronic stable measurements were taken.
angina, on standard antianginal therapy, shown to have Time was allowed for haemodynamic values to return to normal left ventricular function at cardiac catheterisation. baseline (approximately 30 min). ET-1 (Clinalfa, SwitzerBlood was collected into chilled tubes containing 4% land) was then infused at 1, 5 and 15 pmol / min into the EDTA. Samples were kept on ice and were then censame pulmonary artery. Each dose was infused for 20 min trifuged at 48C. Separated plasma samples were immediwith haemodynamic measurements being made at 5 and 15 ately stored at 2208C. ET-1 and big ET-1 were assayed min. Further measurements were taken 5 and 15 min after directly (and separately) using enzyme immunoassays the infusion was complete.
(Biomedica). The kits incorporate an immunoaffinity purified polyclonal capture antibody and a monoclonal 2.4. Intravascular Doppler studies detection antibody, both highly specific for ET (1-21) or big ET . Samples were assayed in duplicate and Intravascular Doppler studies were performed in the first averaged. four patients in an attempt to identify marked vasoconstriction associated with a high local concentration of infused ET-1. A 0.018 inch Doppler guide wire (Flowire, Car-2.5.3. ET (1 -28) assay characteristics diometrics) was passed down the multipurpose catheter and Measuring range 0.1 to 15.6 fmol / ml; crossreactivity positioned in a distal pulmonary artery under fluoroscopic ET-1: 100%, ET-2: 100%, ET-3: ,5%, big ET (1-38): control. Velocity data were recorded on videotape (Flomap, ,1%, big ET (22-38): ,1%. Cardiometrics) and analysed using a computer software system (Tomtek Imaging). Peak instantaneous velocities were analysed, with the formula, (average peak velocity) / 2.5. The guide wire was positioned distal to the tip of the Baseline values are reported as mean6S.D., values thermodilution catheter through which the SNP and ET-1 relating to an intervention are reported as mean6standard were infused. Recordings were made at baseline and at error of the mean (S.E.M.). The primary endpoint of the each dose of SNP and ET-1. Local pulmonary angiography study were the changes in PVR and SVR from baseline to was performed at baseline and at peak dose via the the maximum achieved dose of ET-1. Student's paired multipurpose catheter to allow estimation of the diameter t-test (two-tailed) was used to compare baseline and peak of the pulmonary artery under study.
haemodynamic measurements in the SNP and ET-1 infusion study. 
Results
with ET-1 at 1 pmol / min and only trends to increased SVR at 5 pmol / min. Table 3 demonstrates the peak 3.1. SNP infusion haemodynamic effects of ET-1 infusion in these patients compared to the baseline taken after SNP infusion. At 15 Table 2 demonstrates the haemodynamic effects of SNP pmol / min of ET-1 the HR remained unchanged, MAP rose in these patients. As reported in previous studies SNP by 7%, CO fell by 9% and, consequently, SVR rose by reduced mean arterial pressure (MAP), mean pulmonary 20%. MPAP was unchanged, there were trends to a rise in pressure (MPAP), PCWP and SVR whilst increasing HR PCWP (and hence trends to a fall in transpulmonary and cardiac output (CO). The fall in PVR did not reach gradient) and therefore PVR remained unchanged despite statistical significance ( p50.06). Mild flushing was rethe fall in CO. ported by a minority of patients. This study shows that infusions of ET-1, that achieve ET-1 and big ET-1 concentrations during the study.
plasma concentrations similar to those observed in patients with severe heart failure and pulmonary hypertension,
Control subjects and patients with LVD
cause systemic vasoconstriction in patients with LVD. This Results are demonstrated graphically in Fig. 5 . ET-1 and suggests that ET-1 can act as a circulating hormone, at big ET-1 were higher in LVD patients than controls least in the systemic circulation, in advanced CHF. How-(0.4060.59 vs. 0.1560.12 fmol / ml, p50.02 and ever, we observed little or no change in MPAP or PVR Tables 1 and 2 . during ET-1 infusion. Even administration of ET-1 to arterial plasma concentrations of ET-1, well above the produce very high local concentrations of ET-1 failed to pathophysiological range, and reported a 2 mmHg increase cause local pulmonary vasoconstriction, as measured by in MPAP, with a greater rise in PVR than SVR. PCWP was intravascular Doppler ultrasound.
unchanged. Kiely et al. [25] infused approximately 7 Three studies have reported the effects of exogenous ng / kg / min of ET-1 and reported rises in systemic and ET-1 in healthy volunteers. Wagner et al. [23] infused total pulmonary vascular resistance. However they used ET-1 peripherally at approximately 1 ng / kg / min (we gave noninvasive techniques to estimate haemodynamic change, up to approximately 0.5 ng / kg / min) to achieve a 4.5-fold and could not report changes in PVR as they did not increment in pulmonary arterial plasma concentrations, measure PCWP. Plasma concentrations of ET-1 were not achieving levels compatible with those found in heart measured during ET-1 infusion. In our study, the plasma failure. They reported a small fall in MPAP though PVR concentration of ET-1 obtained after infusion of ET-1 at 15 did not change. Weitzberg et al. [24] infused approximately pmol / min was 1.13 fmol / ml which was comparable to the 10 ng / kg / min to achieve a 20-fold increase in pulmonary plasma concentrations of ET-1 found in patients with a raised MPAP (1.0760.76 fmol / ml). Administration of bosentan, a nonselective ET antagonist, led to a fall in both SVR and PVR in patients with CHF when administered acutely [18] and over a 2 week period [26] . It is possible that the fall in PVR observed during administration of bosentan was passive, secondary to an improvement in cardiac and systemic haemodynamics, rather than due to inhibition of a direct and selective pulmonary vasoconstrictor effect of ET-1. Therefore the studies of bosentan do not prove that ET antagonists specifically reduce PVR.
The lack of an effect of ET-1 in the pulmonary circulation in patients with LVD requires explanation given the in vitro effects of ET-1 in pulmonary arteries and the close correlation between plasma concentrations of ET-1 and pulmonary vascular resistance [10, 17, 18, 27] . ET-1 is secreted abluminally and has been thought to act in a concentrations of ET-1 in the plasma than we did might be required to raise tissue concentrations to pathophysiologiFinally, there was one other important finding in this cal levels and to cause pulmonary vasoconstriction, as study. We have been able to explore the relationship reported in studies of healthy volunteers [24, 25] . Nonethebetween plasma concentrations of ET-1 and big ET-1 in less, we did observe systemic vasoconstriction at patients with heart failure and normal controls. True pathophysiological plasma concentrations of ET-1. One plasma concentrations of ET-1, as opposed to measureexplanation for a differential effect on the systemic and ments of irET-1 that include big ET-1, have not often been pulmonary circulations may be that concentrations of ET-1 measured in patients with heart failure [10, 16, 17] . Wei et at the pulmonary vascular smooth muscle cell are already al. measured ET-1 and big ET-1 separately in four healthy high and exogenous ET-1 in the doses that we gave may volunteers and four patients with severe heart failure [12] . not have resulted in a further substantial increase in tissue Big ET-1 was not detected in the plasma of healthy ET-1 concentrations. Alternatively, there may be differenvolunteers but accounted for over 60% of irET-1 in tial regulation of ET and ET mediated responses in the patients with severe heart failure. In a larger population we A B pulmonary and systemic circulations in heart failure. For could detect big ET-1 even in healthy volunteers. In instance impaired systemic or enhanced pulmonary endopatients with heart failure and normal pulmonary artery thelial ET mediated vasodilatation may occur.
pressures only big ET-1 was raised compared to controls.
B ET-1 does cause pulmonary vasoconstriction in vitro at However, in patients with severe heart failure and raised the plasma concentrations we observed, but in this preparapulmonary artery pressures (MPAP .30 mmHg), both tion vessels are bathed in ET-1, and ET-1 may act ET-1 and big ET-1 were elevated, the increase in ET-1 predominantly and directly on vascular smooth muscle being relatively greater than the increase in big ET-1 (see ET and ET receptors [27] . In contrast, exogenously After a period of rest to achieve stable baseline haemobetween plasma ET-1 and PVR? Elevated plasma ET-1 dynamics each study began with an infusion of SNP to concentrations could merely be a marker of endothelial assess pulmonary vascular responsiveness. Despite a 30 dysfunction. There is considerable evidence for endothelial min wash out period during which mean systemic and dysfunction in patients with heart failure, and in many pulmonary arterial pressures were noted to have returned respects this dysfunction reflects endothelial hyperactivity.
to normal some rebound increase in PVR and SVR was In CHF patients von Willebrand factor, a glycoprotein noted. This could have obscured a small increase in PVR released from endothelial cells, is elevated and correlates during infusion of ET-1. Even if this were the case any rise directly not only with PVR [31] but also with plasma in PVR was no greater than the increase in SVR and a concentrations of ET [32]. Habib et al. showed an enpreferential vasoconstrictor effect in the pulmonary circu-G hanced response to N -monomethyl-L-arginine in patients lation can be excluded. with heart failure suggesting enhanced basal nitric oxide As we were unable to demonstrate changes in local production in heart failure [33] . Endothelial derived vasopulmonary blood flow, whilst observing systemic changes dilator prostaglandins are also increased in heart failure in response to ET-1 infusion, we discontinued the in- [34] .
travascular Doppler studies after only four patients. It is Alternatively, the association between high plasma ET-1 possible that we could have missed small changes in local concentrations and pulmonary haemodynamic measurepulmonary vascular resistance that could have been dements may be explained by the postulated role of the tected with a much larger number of patients. However, pulmonary circulation in ET-1 clearance. The pulmonary any major local pulmonary vascular effect of ET-1 is vasculature has been reported to be a major site of effectively excluded even with this small number of synthesis [17, 35] and of clearance of ET-1 in many observations. [23, 24, 35] but not all [36, 37] studies. Increased plasma ET-1 could reflect reduced clearance and / or increased synthesis of ET-1 in severe CHF. A recent report sug-5. Conclusion gested that the pulmonary clearance of ET-1 in heart failure is inversely related to the severity of pulmonary ET-1, when infused into patients with LVD to achieve hypertension [38] . The authors concluded that elevated plasma concentrations in keeping with patients with severe plasma ET-1 concentrations are a marker of pulmonary heart failure and pulmonary hypertension, causes systemic hypertension and reflect pulmonary endothelial dysfuncvasoconstriction with little or no effect on the pulmonary tion.
vasculature. ET-1, in addition to having paracrine effects, 
